- FDA Law Blog had a post Thursday about "The Dog Ate My Homework Act," which would give a reprieve to companies that miss the deadline for filing a patent term extension request.
- Pharmalot had this post Wednesday, reporting that Congress has delayed the FDA bill until September.
- Patently-O reported Wednesday on the Federal Circuit's decision on Washington, D.C.'s drug price law. PhRMA made a press release on the decision. The Washington Post published this article on the case.
- Tuesday, Wyeth announced a deal with Teva and Sun concerning generic Protonix. Today, Teva announced that FDA approved its ANDA for Protonix.
- Investor's Business Daily had an interesting article last week, "RNAi Stirs Excitement in Big Pharma."
- The Patent Prospector had a neat post last week, "Dealing with KSR."
Editor
About
- The Orange Book blog team are a group of attorneys with McAndrews, Held and Malloy, which is a full-service IP firm representing both brands and generics in various aspects of IP law. This blog does not provide legal advice. If you are seeking legal advice, please contact the author directly.
Disclaimer
- Orange Book Blog is published for informational purposes only; it contains no legal advice whatsoever. Publication of Orange Book Blog does not create an attorney-client relationship. Orange Book Blog is not edited by McAndrews, Held & Malloy, Ltd. ("MHM") or its clients. The views expressed are solely those of the authors, and may not reflect the views of MHM or its clients. No part of Orange Book Blog--whether information, commentary, or other--may be attributed to MHM or its clients. MHM represents many companies in the pharmaceutical and biotechnology industries, and therefore Orange Book Blog may occasionally report on news that relates to MHM clients. Orange Book Blog will always strive to be unbiased. All information on Orange Book Blog should be double-checked for its accuracy and current applicability.
Susbscribe
« Federal Circuit Affirms Denial of Somerset Pharma's Interim Patent Term Extension on Depression Patch | Main | Pharma News Briefs »
August 03, 2007
The comments to this entry are closed.
Susbscribe
Search
Categories
- 180-Day Exclusivity (26)
- 271(e)(1) Safe Harbor (11)
- 271(e)(2) Jurisdiction (2)
- 30-Month Stay (3)
- Antitrust (49)
- Authorized Generics (20)
- Biosimilars (33)
- Citizen Petitions (22)
- Claim Construction (1)
- Claim Preclusion (1)
- Collateral Estoppel (2)
- Conferences (92)
- Declaratory Judgment Jurisdiction (25)
- FDA Announcements (7)
- FDA Litigation (12)
- Inequitable Conduct (4)
- Infringement--271(g) (1)
- Infringement--Direct (4)
- Infringement--Indirect (7)
- Inter Partes Review (6)
- Issue Preclusion (2)
- Orange Book Issues (27)
- Paragraph IV Cases (207)
- Patent Eligibility (2)
- Patent Term Extension (13)
- Pediatric Exclusivity (14)
- Pharma Business News (38)
- Preliminary Injunction (2)
- Prosecution (1)
- Section viii Statements (5)
- Validity--Novelty (6)
- Validity--Obviousness (22)
- Validity--Section 101 (2)
- Validity--Section 112 (6)
Comments